Financial Data and Key Metrics Changes - In 2025, the company achieved over 7% top-line growth and 13% adjusted EPS growth, with margins improving by over 50 basis points [5][13] - For the fourth quarter, enterprise revenue increased by 5.6% year-over-year, with adjusted EPS growing by 18% [10][14] - Free cash flow for the quarter was $490 million, down from $665 million the previous year, primarily due to working capital timing [15] Business Line Data and Key Metrics Changes - Diagnostics revenue for the fourth quarter was $2.7 billion, up 5.5% year-over-year, with organic growth of 4.1% [16] - Biopharma Laboratory Services (BLS) revenue increased by 3.4%, with Central Labs performing well and revenue growing 11.1% [17] - The adjusted operating income for Diagnostics was $419 million, or 15.4% of revenue, compared to $316 million, or 13.9% of revenue last year [16] Market Data and Key Metrics Changes - The company reported a strong trailing 12-month book-to-bill ratio of 1.09, driven by Central Labs [13][18] - The backlog for BLS was $8.7 billion, with an expectation of approximately $2.7 billion converting into revenue over the next 12 months [18] Company Strategy and Development Direction - The company aims to deepen partnerships with health systems and local laboratories, having signed or closed 13 deals contributing to over $1 billion in revenue growth [5][6] - A strategic investment is planned for a new central laboratory facility to support growth and demand, with construction expected to begin later this year [9][21] - The company continues to focus on specialty testing, having launched over 130 new tests in 2025, particularly in oncology, women's health, and neurology [7][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong underlying business performance for 2026, expecting full-year enterprise revenue growth of 5.4% and adjusted EPS growth of approximately 9% [11][20] - The delay of PAMA through December 31, 2026, was viewed positively, but management emphasized the need for permanent reform [11][56] - Management noted that the diagnostic market remains strong, with expectations to outperform overall market growth [48] Other Important Information - The company announced the retirement of two executive vice presidents, effective April 1, with successors appointed [12] - The company plans to reinvest a portion of the savings from the PAMA delay into its business for long-term growth [88] Q&A Session Summary Question: Guidance for 2026 contributions from price and volume - Management expects revenue growth of 5%-6% in diagnostics, with half of the organic growth coming from volume and half from price mix [27][30] Question: Contributions from Invitae integration - The integration of Invitae has gone well, with expected revenue growth in specialty areas, but specific breakout of Invitae's performance will no longer be provided [32] Question: Fourth quarter organic volume performance - Organic volume growth was impacted by lower referrals from a large consumer genetic client and weather conditions, but adjustments indicate consistent growth [36][39] Question: Competitive landscape in diagnostics - Management believes the diagnostic market is strong, with a focus on hospital partnerships and specialty testing driving growth [48] Question: PAMA implications and survey submission - Management is prepared to submit data for PAMA and continues to advocate for the RESULTS Act as a permanent solution [55][56] Question: Early Development market growth and pricing - Early Development is expected to remain flat in 2026, with ongoing consolidation efforts to improve margins [66] Question: New oncology tests and revenue expectations - The company is well-positioned in precision oncology testing, with expectations for strong growth in new tests launched [69]